- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
GSK and AstraZeneca are seeking FDA approval for new specialty medicines amid market competition.
1 report, 0 independent
Updated Jul 9
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
GSK and AstraZeneca are seeking FDA approval for new specialty medicines amid market competition.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
-
GSK
British multinational pharmaceutical and biotechnology company
Nothing else this week.
-
AstraZeneca
British-Swedish pharmaceutical company
- FDA
Related events
- FDA refused Summit Therapeutics' drug, and the stock's market performance was compared to Nasdaq.
- Summit Therapeutics and AstraZeneca announced a partnership on July 4, 2025, to collaborate on lung cancer drug development.
- FDA approves generic drug market entry, with Lanreotide challenging Somatuline Depot market share.
- ADC Therapeutics received accelerated approval for its drug from the FDA.
- FDA placed a clinical hold on the drug application submitted by Bright Minds Biosciences Inc.
Coverage
Newest first; wire copies grouped- Unknown outlet